Mechanism
Liraglutide is a GLP-1 receptor agonist with a fatty-acid (palmitic acid) modification at lysine-26, which allows reversible binding to albumin and extends the half-life from GLP-1’s native ~2 minutes to approximately 13 hours. The half-life supports once-daily subcutaneous dosing.
The receptor pharmacology is the same as semaglutide and the rest of the GLP-1 class: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite reduction. The dose-effect profile is somewhat shallower than semaglutide — 1.8mg liraglutide produces ~1.0–1.1% HbA1c reduction in T2D versus semaglutide 1mg’s ~1.5%, and 3.0mg liraglutide produces ~5–8% weight loss versus semaglutide 2.4mg’s ~15%.
The molecular relationship is direct: liraglutide came first, semaglutide is a more aggressively-engineered version of the same template, tirzepatide is a parallel-track innovation that adds GIP agonism.
What the evidence shows
Selected pivotal trials:
- LEAD-1 through LEAD-6 (2008–2010): T2D pivotal trials versus placebo and active comparators. Established efficacy and safety leading to FDA approval.
- SCALE-Obesity, SCALE-Diabetes (2013–2015): Obesity pivotal trials at 3mg dose. Mean weight loss ~5–8% versus 2–3% with placebo.
- LEADER (2016): Cardiovascular safety / efficacy trial in 9,340 T2D patients with high CV risk. 13% relative risk reduction in MACE versus placebo. The outcome that established cardiovascular benefit for the GLP-1 class.
- SUSTAIN-3 (2018): Head-to-head versus liraglutide; semaglutide showed superior glycemic and weight effects. Liraglutide remains effective; just less so.
- PIONEER trials (oral semaglutide development) used liraglutide as one of the active comparators, providing additional head-to-head context.
The evidence base is long. Liraglutide has been used in millions of patient-years; the post-marketing safety profile is well-characterized.
Dosing literature
Approved dosing (subcutaneous, once daily):
- Type 2 diabetes (Victoza): 0.6mg → 1.2mg → 1.8mg, with weekly titration steps to manage GI tolerability
- Obesity (Saxenda): 0.6mg → 1.2mg → 1.8mg → 2.4mg → 3.0mg, with weekly titration steps; target dose is 3.0mg
Daily dosing means tolerability events (nausea, in particular) recur more frequently than with weekly drugs. For some patients this is a feature — predictable timing — and for others it’s a disadvantage. The behavioral commitment of daily injection is real.
Risks and adverse events
Common: Nausea (~25%), vomiting, diarrhea, constipation, headache, decreased appetite. Most are dose-dependent and improve with slower titration.
Less common but important:
- Acute pancreatitis — case reports across the class; signal exists but absolute risk is low
- Gallbladder disease — increased rate, particularly with rapid weight loss
- Diabetic retinopathy — class effect with rapid HbA1c improvement
- Hypoglycemia — uncommon as monotherapy; combination with insulin or sulfonylureas requires dose adjustment
Pre-clinical / theoretical: MTC C-cell tumors in rodents (class effect); contraindicated with personal/family history of MTC or MEN2.
Injection site reactions are slightly more common with daily dosing than weekly drugs, simply because injection events are more frequent.
Regulatory status
| Region | Diabetes | Obesity | Notes |
|---|---|---|---|
| United States | Approved (Victoza) | Approved (Saxenda) | Generics emerging as patents expire. |
| European Union | Approved | Approved | Same brand names. |
| United Kingdom | Approved | Approved | NHS access criteria apply. |
| Canada | Approved | Approved | |
| Australia | Approved | Approved | |
| Japan | Approved | Approved |
The patent landscape is shifting: the core liraglutide patent expired in major markets in 2024–2025, with generic and biosimilar versions launching. Pricing dynamics are still settling.
Where to get it
Clinician relationship, prescription, licensed pharmacy. Same posture as the rest of the GLP-1 class — self-sourcing is not a category we endorse.
We have no fulfillment partner for liraglutide at this time. (See How we make money.)
References (selected)
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016 (LEADER). PubMed
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015 (SCALE-Obesity).
- Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono). Lancet 2009.
- FDA prescribing information, Victoza and Saxenda — current revisions.
Quick Facts
| Also Known As | NN2211, Victoza, Saxenda |
|---|---|
| Sequence | His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Molecular Formula | C172H265N43O51 |
| Molecular Weight | 3751 Da |
| PubChem CID | 16134956 |
Research Parameters
| Half-Life | ~13 hours |
|---|---|
| Stability | Unopened, lyophilized powder is stable according to the manufacturer's labeled expiry date when stored properly. After reconstitution according to manufacturer instructions, the solution should be stored refrigerated. Specific stability data for research-grade lyophilized material is variable; a conservative estimate is 28 days at 2-8°C after reconstitution in appropriate solvent. |
| Solubility | For clinical use, provided in a pre-filled pen device. For research purposes with lyophilized material, reconstitution is typically performed with sterile water for injection or bacteriostatic water (containing 0.9% benzyl alcohol). |
| Storage (Lyophilized) | -20°C, protect from light and moisture. For long-term storage, desiccate at -20°C or below. |
| Storage (Reconstituted) | 2-8°C (refrigerated, do not freeze). Use within the timeframe specified by the manufacturer or research supplier (e.g., 30 days). Protect from light. |
| Typical Research Dose | In human clinical research: 600-3000 mcg (0.6-3.0 mg) once daily. In animal research, doses are species-specific and typically reported in mcg/kg. |
| Cycle Parameters | In clinical research for chronic conditions: Daily subcutaneous injection, often with a dose-escalation period over several weeks. Treatment is typically continuous for the duration of the study, which can be months to years, without defined 'on/off' cycles. |
| Amino Acid Count | 31 |
Mechanism of Action
Liraglutide exerts its effects primarily through selective, high-affinity binding to the GLP-1 receptor, a G-protein coupled receptor expressed on pancreatic beta-cells, alpha-cells, and in various regions of the brain, heart, and gastrointestinal tract. This binding initiates multiple intracellular signaling pathways.
cAMP/PKA Pathway: Activation of the GLP-1 receptor stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This activates protein kinase A (PKA) and the cAMP-regulated guanine nucleotide exchange factor II (Epac2), leading to the closure of ATP-sensitive potassium (KATP) channels, membrane depolarization, opening of voltage-dependent calcium channels (VDCC), and subsequent calcium influx. This cascade potentiates glucose-dependent insulin secretion from pancreatic beta-cells.
Glucagon Suppression: In pancreatic alpha-cells, GLP-1 receptor activation suppresses glucagon secretion via both direct PKA-mediated pathways and indirect paracrine effects from neighboring beta-cells (possibly via somatostatin or insulin), thereby reducing hepatic glucose production.
Central Satiety Signaling: Liraglutide crosses the blood-brain barrier in limited regions and activates GLP-1 receptors in key hypothalamic nuclei (e.g., arcuate nucleus) and the brainstem. This activation promotes feelings of satiety, reduces appetite, and delays gastric emptying, contributing to reduced caloric intake and weight loss.
Beta-cell Proliferation and Protection: Preclinical studies indicate that liraglutide signaling through PKA, Epac2, and PI3K/Akt pathways can stimulate beta-cell proliferation, inhibit apoptosis, and enhance neogenesis, thereby potentially preserving beta-cell mass and function.
Research Applications
Glycemic Control in Type 2 Diabetes: Liraglutide has been extensively studied for its ability to improve glycemic control. It lowers fasting and postprandial plasma glucose levels primarily through glucose-dependent insulin secretion and glucagon suppression. Clinical trials demonstrate significant reductions in HbA1c, with a low intrinsic risk of hypoglycemia when used without sulfonylureas or insulin.
Weight Management and Obesity: Liraglutide induces dose-dependent weight loss by reducing appetite and energy intake through central actions on satiety centers and by slowing gastric emptying. At a higher dose (3.0 mg), it is approved specifically for chronic weight management in obesity, with research showing sustained reductions in body weight and improvement in cardiometabolic risk factors.
Cardiovascular Outcomes: Large-scale cardiovascular outcome trials have investigated liraglutide's effects on major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk. Research indicates it can reduce the risk of MACE, potentially through mechanisms involving weight loss, blood pressure reduction, improved lipid profiles, and direct cardioprotective effects.
Neuroprotection: Preclinical research in animal models of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, suggests liraglutide may exert neuroprotective effects. Proposed mechanisms include reducing neuroinflammation, attenuating amyloid-beta plaque formation, improving neuronal insulin signaling, and promoting synaptic plasticity. These findings are investigational and not yet translated to clinical practice.
Non-Alcoholic Steatohepatitis (NASH): Research is exploring liraglutide's potential in NASH, a progressive form of fatty liver disease. Benefits may stem from weight loss, improved insulin sensitivity, and direct anti-inflammatory and anti-fibrotic effects on hepatocytes, with some clinical trials showing reductions in liver fat and inflammation.
Safety & Side Effects
The most common side effects reported in clinical trials are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These effects are usually mild to moderate and transient, diminishing over time. Anecdotally, reports of injection site reactions, headache, and transient increases in heart rate have been noted. Serious but rare adverse events include pancreatitis; research subjects with a history of pancreatitis are generally excluded. Theoretical concerns based on rodent toxicology studies include a potential risk of medullary thyroid carcinoma (MTC) associated with GLP-1 receptor agonism, as liraglutide causes thyroid C-cell tumors in rodents. This effect is not established in humans, but liraglutide is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Hypoglycemia risk is low when used without insulin secretagogues.
Dosage Information
Disclaimer: The following information is derived from published clinical and preclinical research literature and is presented for educational and research purposes only. It does not constitute medical advice.
In clinical research for type 2 diabetes, liraglutide is typically initiated at 0.6 mg subcutaneously once daily for one week to minimize gastrointestinal side effects, then increased to 1.2 mg daily. The maximum approved dose is 1.8 mg once daily. For obesity research, the dosing protocol escalates from 0.6 mg to 3.0 mg once daily over several weeks. The primary route of administration is subcutaneous injection into the abdomen, thigh, or upper arm. Administration is recommended at any time of day, independent of meals, but at a consistent time. Duration of use in long-term studies has extended for several years for chronic management of diabetes and obesity.
References
1. Buse, J.B., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009.
2. Marso, S.P., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016.
3. Pi-Sunyer, X., et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 2015.
4. Drucker, D.J., et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006.
5. Astrup, A., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet, 2009.
6. Knudsen, L.B., et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology, 2010.
7. Armstrong, M.J., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016.
8. During, M.J., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine, 2003.